The Move From Single-Target to Multi-Receptor Metabolic Compounds
UpdatedNo single switch controls metabolism, so it makes sense that metabolic research moved away from one-receptor compounds toward molecules that act on several receptors at once. The incretin field shows this most clearly, and it is why "multi-pathway" has become such a common phrase. This is a research summary for laboratory use only.
From one receptor to two
GLP-1 receptor agonists set the pattern. The next step paired GLP-1 with a second incretin receptor, GIP. That dual-agonist approach is the one studied with tirzepatide, and mechanistic reviews cover how the combined pharmacology works (Nauck & D'Alessio, Cardiovasc Diabetol, 2022). [1]
Note: Several of these compounds are approved drugs. Semaglutide was approved by the FDA as Ozempic (2017), Rybelsus (2019) and Wegovy (2021). Tirzepatide was approved as Mounjaro (2022) and Zepbound (2023). Approval of a drug product does not extend to research-grade material sold for laboratory use.
A third receptor
Triple agonists add glucagon-receptor activity, which is linked to energy expenditure, on top of GLP-1 and GIP. Retatrutide is the reference example, first described as a new GLP-1/GIP/glucagon agonist (Coskun et al., Cell Metab, 2022). [2] The idea is hypothesized rather than proven: acting on complementary points in the system may achieve more than pushing one point as hard as possible.
Combinations beyond the incretins
The same multi-pathway reasoning appears in research that pairs metabolic agonists with compounds aimed at mitochondrial function. The underlying point is that hormonal signaling and cellular energy are two different controls on one system.
Note: These compounds are studied in research and clinical-trial settings, and that does not make human use appropriate here. Everything discussed is for laboratory Research Use Only.
FAQ
Why target several receptors rather than one?
Metabolism is governed by several overlapping systems. Dual and triple agonist research asks whether acting on complementary receptors is hypothesized to give broader effects than maxing out a single target.
References
For research use only. Nothing on Chemical Messenger is medical advice or a recommendation for human use.